Which Factors Contribute to False-Positive, False-Negative, and Invalid Results in Fetal Fibronectin Testing in Women with Symptoms of Preterm Labor?

Abstract

Objective We assessed the influence of external factors on false-positive, false-negative, and invalid fibronectin results in the prediction of spontaneous delivery within 7 days.

Methods We studied symptomatic women between 24 and 34 weeks' gestational age. We performed uni- and multivariable logistic regression to estimate the effect of external factors (vaginal soap, digital examination, transvaginal sonography, sexual intercourse, vaginal bleeding) on the risk of false-positive, false-negative, and invalid results, using spontaneous delivery within 7 days as the outcome.

Results Out of 708 women, 237 (33%) had a false-positive result; none of the factors showed a significant association. Vaginal bleeding increased the proportion of positive fetal fibronectin (fFN) results, but was significantly associated with a lower risk of false-positive test results (odds ratio [OR], 0.22; 95% confidence intervals [CI], 0.12–0.39). Ten women (1%) had a false-negative result. None of the investigated factors was significantly associated with a significantly higher risk of false-negative results. Twenty-one tests (3%) were invalid; only vaginal bleeding showed a significant association (OR, 4.5; 95% CI, 1.7–12).

Conclusion The effect of external factors on the performance of qualitative fFN testing is limited, with vaginal bleeding as the only factor that reduces its validity.

Keywords

fetal fibronectin - preterm delivery - prediction - external factors

• References

• 1 Matsuura H, Takio K, Titani K , et al. The oncofetal structure of human fibronectin defined by monoclonal antibody FDC-6. Unique structural requirement for the antigenic specificity provided by a glycosylhexapeptide. J Biol Chem 1988; 263 (7) 3314-3322
• 2 Lockwood CJ, Senyei AE, Dische MR , et al. Fetal fibronectin in cervical and vaginal secretions as a predictor of preterm delivery. N Engl J Med 1991; 325 (10) 669-674
• 3 Defranco EA, Lewis DF, Odibo AO. Improving the screening accuracy for preterm labor: is the combination of fetal fibronectin and cervical length in symptomatic patients a useful predictor of preterm birth? A systematic review. Am J Obstet Gynecol 2013; 208 (3) 233.e1-233.e6
• 4 Hologic I. Fetal fibronectin specimen collection. 2009. Available at http://www.ffntest.com/pdfs/rapid_ffn_speccollectkit_ifu.pdf . Accessed December 1, 2015
• 5 van Baaren GJ, Vis JY, Wilms FF , et al. Predictive value of cervical length measurement and fibronectin testing in threatened preterm labor. Obstet Gynecol 2014; 123 (6) 1185-1192
• 6 Ben-Haroush A, Poran E, Yogev Y, Glezerman M. Vaginal fetal fibronectin evaluation before and immediately after ultrasonographic vaginal cervical length measurements in symptomatic women at risk of preterm birth: a pilot study. J Matern Fetal Neonatal Med 2010; 23 (8) 854-856
• 7 Faron G, Buyl R, Foulon W. Does recent sexual intercourse during pregnancy affect the results of the fetal fibronectin rapid test? A comparative prospective study. J Perinat Med 2015; 43 (4) 403-408
• 8 McLaren JS, Hezelgrave NL, Ayubi H, Seed PT, Shennan AH. Prediction of spontaneous preterm birth using quantitative fetal fibronectin after recent sexual intercourse. Am J Obstet Gynecol 2015; 212 (1) 89.e1-89.e5
• 9 Lukes AS, Thorp Jr JM, Eucker B, Pahel-Short L. Predictors of positivity for fetal fibronectin in patients with symptoms of preterm labor. Am J Obstet Gynecol 1997; 176 (3) 639-641
• 10 Donders AR, van der Heijden GJ, Stijnen T, Moons KG. Review: a gentle introduction to imputation of missing values. J Clin Epidemiol 2006; 59 (10) 1087-1091
• 11 Greenland S, Finkle WD. A critical look at methods for handling missing covariates in epidemiologic regression analyses. Am J Epidemiol 1995; 142 (12) 1255-1264
• 12 van der Heijden GJ, Donders AR, Stijnen T, Moons KG. Imputation of missing values is superior to complete case analysis and the missing-indicator method in multivariable diagnostic research: a clinical example. J Clin Epidemiol 2006; 59 (10) 1102-1109
• 13 Goodwin TM, Millar L, North L, Abrams LS, Weglein RC, Holland ML. The pharmacokinetics of the oxytocin antagonist atosiban in pregnant women with preterm uterine contractions. Am J Obstet Gynecol 1995; 173 (3 Pt 1) 913-917
• 14 Tsatsaris V, Cabrol D, Carbonne B. Pharmacokinetics of tocolytic agents. Clin Pharmacokinet 2004; 43 (13) 833-844
• 15 Haas DM, Imperiale TF, Kirkpatrick PR, Klein RW, Zollinger TW, Golichowski AM. Tocolytic therapy: a meta-analysis and decision analysis. Obstet Gynecol 2009; 113 (3) 585-594
• 16 Abbott DS, Radford SK, Seed PT, Tribe RM, Shennan AH. Evaluation of a quantitative fetal fibronectin test for spontaneous preterm birth in symptomatic women. Am J Obstet Gynecol 2013; 208 (2) 122.e1-122.e6
• 17 Kątnik-Prastowska I, Orczyk-Pawiłowicz M. Expression and potential biological role of α(1,2)fucosylated glycotopes on amniotic and seminal fibronectins. Biochem Soc Trans 2011; 39 (1) 355-359
• 18 Feinberg RF, Kliman HJ, Bedian V, Monzon-Bordonaba F, Menzin AW, Wang CL. Monoclonal antibody X18A4 identifies an oncofetal fibronectin epitope distinct from the FDC-6 binding site. Am J Obstet Gynecol 1995; 172 (5) 1526-1536